{"denoms":[{"counts":[{"groupId":"BG000","value":"71"}],"units":"Participants"}],"groups":[{"description":"Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.","id":"BG000","title":"PTCL Subtype"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.52","value":"54.5"}]}],"title":"Age(years)"}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"47"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"71"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71"}]}],"title":"China"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"}],"title":"PTCL not otherwise specified (NOS)"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Angioimmunoblastic T-cell lymphoma"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Anaplastic large cell lymphoma, ALK+"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Anaplastic large cell lymphoma, ALK-"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Extranodal NK/T-cell lymphoma - nasal type"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Subcutaneous panniculitis-like T-cell lymphoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Enteropathy-associated T cell lymphoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Adult T-cell lymphoma/leukemia (human T-cell leuke"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"other"}],"title":"Subtype of PTCL from investigator"},{"categories":[{"measurements":[{"groupId":"BG000","value":"34"}],"title":"PTCL not otherwise specified (NOS)"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Angioimmunoblastic T-cell lymphoma"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Anaplastic large cell lymphoma, ALK+"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Anaplastic large cell lymphoma, ALK-"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Extranodal NK/T-cell lymphoma - nasal type"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Subcutaneous panniculitis-like T-cell lymphoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Enteropathy-associated T cell lymphoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Adult T-cell lymphoma/leukemia (human T-cell leuke"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"other"}],"title":"Subtype of PTCL from central review"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline Characteristics","unitOfMeasure":"Participants"}],"populationDescription":"Safety population is 71"}